StockData
BeyondSpring Inc. logo

BeyondSpring Inc. (BYSI) stock

BYSINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 4/30
$0.60+0.00 (+0.03%)

Close on Nov 13, 2026Market cap $24.72MP/E –Yield –

Earnings

BeyondSpring's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 24, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
$1.24
-$0.04 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of BeyondSpring's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 24, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 13, 2026after the close––$1.24Release
Q2 FY2026ended Jun 30, 2026Aug 14, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open–––Release
Q4 FY2025ended Dec 31, 2025Mar 25, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open––-$0.04Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025before the open–––Release
Q1 FY2025ended Mar 31, 2025May 12, 2025after the close–––Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

BeyondSpring has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When BeyondSpring puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases BeyondSpring filed with the SEC as exhibits to Form 8-K or 6-K

  1. BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
    Results
  2. BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
    News
  3. BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
    Results
  4. BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
    Update
  5. BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
    Results
  6. BeyondSpring Reports 2025 Year-End Financial Results
    Results
  7. BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
    Results
  8. SEED Therapeutics Completes $30 Million Series A-3 Financing
    News
  9. BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
    Results
  10. BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
    Results
  11. BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
    Results
  12. Unaudited Pro Forma Condensed Consolidated Financial Information
    News
  13. BeyondSpring Announces $35.4 Million Sale of a Portion of Equity
    News
  14. SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology
    6-K
  15. BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
    6-K

See a number that looks wrong?